4SG.F SOL-GEL TECHN. IS-10
- Market cap
- EUR 177M
- P/E
- -
- P/B
- 4.01x
- ROE
- -30.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 4SG.F undervalued?
Graham numberThe Graham number of SOL-GEL TECHN. IS-10 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
SOL-GEL TECHN. IS-10 fundamental analysis
No fundamental analysis for SOL-GEL TECHN. IS-10 yet.
SOL-GEL TECHN. IS-10 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About SOL-GEL TECHN. IS-10
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in…
Full company profileSOL-GEL TECHN. IS-10 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
SOL-GEL TECHN. IS-10 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 31.3M | 3.88M | 1.55M | 11.5M | 19.4M | 1.40M |
| Operating Income | 2.96M | -16.2M | -29.3M | -12.0M | -7.54M | -16.0M |
| EBITDA | - | -15.7M | -29.0M | -11.8M | -7.43M | -16.0M |
| Net Income | 3.22M | -14.9M | -27.2M | -10.6M | -6.13M | -14.8M |
| EPS | 1.39 | -6.45 | -9.78 | -3.80 | -2.20 | -4.53 |
| Balance Sheet | ||||||
| Total Assets | 69.2M | 46.6M | 45.3M | 35.8M | 29.9M | 53.8M |
| Total Liabilities | 13.6M | 4.42M | 6.64M | 7.00M | 7.11M | 5.66M |
| Shareholders' Equity | 55.6M | 42.2M | 38.6M | 28.9M | 22.8M | 48.1M |
| Cash & Short-term Investments | 20.1M | 12.4M | 7.51M | 19.5M | 11.0M | 16.7M |
| Cash Flow | ||||||
| Operating Cash Flow | -7.69M | -9.48M | -17.7M | -13.9M | 322K | - |
| Capital Expenditure | 143K | 171K | 134K | 2.00K | 47.0K | 0.00 |
| Free Cash Flow | -7.83M | -9.66M | -17.9M | -13.9M | 275K | - |
| Ratios | ||||||
| ROE | 5.8% | -35.4% | -70.5% | -36.7% | -26.9% | -30.8% |
| ROA | 4.7% | -32.0% | -60.1% | -29.5% | -20.5% | -27.6% |
| Net Profit Margin | 10.3% | -384.3% | -1,752.8% | -91.7% | -31.6% | -1,059.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
SOL-GEL TECHN. IS-10 dividends
SOL-GEL TECHN. IS-10 has not paid dividends in the last 5 fiscal years.
Last stock split: 1:10 on May 5, 2025.
Who owns SOL-GEL TECHN. IS-10
- Insiders 59.73%
- Institutions 40.27%
- Public & others 0.00%
- Shares outstanding 3.27M
- Free float 353K
SOL-GEL TECHN. IS-10 company profile
- Company name
- SOL-GEL TECHN. IS-10
- Ticker
- 4SG.F
- ISIN
- IL0011417206
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 28
- Fiscal year end
- December
- Address
- 7 Golda Meir Street, Ness Ziona, Israel, 7403650
- Phone
- 972 8 931 3433
- Website
- sol-gel.com
About SOL-GEL TECHN. IS-10
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
SOL-GEL TECHN. IS-10 management
5- Mr. Eyal Ben-OrChief Financial Officer · born 1984
- Dr. Itzik YosefChief Operating Officer · born 1976
- Mr. Michael GlezinChief Business Officer · born 1983
- Dr. Ofer ToledanoVice President of Research & Development · born 1965
- Mr. Moshe ArkinCEO & Executive Chairman · born 1953